A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

Inclusion Criteria: * Healthcare professionals working only in Saudi Arabia AND * Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR * Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR * Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion Exclusion Criteria: * Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies) * Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome * Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\]) * Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.